Emergent BioSolutions Inc. (EBS) Report Analysis
Corporate Events
Emergent BioSolutions Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
2022-06-24 10:30:00
Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted). AV7909 is the company's new anthrax vaccine candidate evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. The Prescription Drug User Fee Act goal date for a decision by the FDA is in April 2023. The rolling BLA submission, completed in April 2022, is based on data from the pivotal phase 3 clinical study of AV7909 that evaluated the lot consistency, immunogenicity, and safety of the vaccine candidate following a two-dose schedule administered intramuscularly in healthy adults. It also included data from the phase 2 study that evaluated non-interference between AV7909 and antibacterial drugs approved for post-exposure prophylaxis of anthrax disease. The BLA submission was completed under contract HHSO100201600030C for the advanced development and delivery of AV7909, funded by the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.
Emergent BioSolutions Inc. Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
2022-06-21 10:30:00
Emergent BioSolutions Inc. announced that two-year persistence data from its phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate were published in The Lancet Infectious Diseases. This randomized, double-blind, parallel-group, phase 2 study was conducted at three U.S. sites with 415 participants. Eligible participants were healthy CHIKV-naïve adults aged 18–45 years. The primary endpoint was the geometric mean titer of anti-CHIKV neutralizing antibody on day 57 (28 days after the last vaccination). Safety was also assessed. Emergent’s CHIKV VLP vaccine candidate was well tolerated and induced a robust and durable serum neutralizing antibody immune response against the Chikungunya virus up to two years. A single dose, 40 µg injection of adjuvanted CHIKV VLP is being further investigated in phase 3 clinical trials.
Emergent Biosolutions Inc. and Emergent Manufacturing Operations Baltimore, LLC Enters into Manufacturing Services Agreement with Janssen Pharmaceuticals, Inc
2022-06-06 12:03:00
On July 2, 2020, Emergent BioSolutions Inc., through its wholly-owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC (collectively, the “Company”), entered into a manufacturing services agreement with Janssen Pharmaceuticals Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing of Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac® technology. On June 6, 2022, the Company provided to Janssen a notice (the “Notice”) of material breach of the Agreement for, among other things, (i) failure by Janssen to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Agreement; (ii) to confirm Janssen’s intent to not purchase the requisite minimum quantity of the Product pursuant to the Agreement; and (iii) instead, wind-down the Agreement ahead of fulfilling these minimum requirements. The Agreement provides, in pertinent part, the following terms, among others, for notice, cure, and termination: Janssen has the right to terminate the Agreement by written notice to the Company (a) if thirty (30) days following receipt by the Company of written notice from Janssen of a material breach of the Agreement, the Company has failed to start and diligently pursue the cure of such breach, and (b) upon twelve (12) months’ advance written notice if Janssen decides to stop selling the Product. The Company has the right to terminate the Agreement by written notice to Janssen if thirty (30) days following receipt by Janssen of written notice from the Company of a material breach of the Agreement Janssen has failed to cure such breach. Upon notification of termination, the Company agrees to promptly cease performing services under the Agreement and to take reasonable steps to mitigate expenses incurred therewith. Termination of the Agreement will not affect the obligation of either party to make any payments for which it is liable prior to or upon such termination, including payment by Janssen for certain raw materials purchased pursuant to the Agreement prior to its termination, and payment by Janssen for all services related to the required minimum quantity. Under the terms of the Agreement, the Company had agreed to provide contract development and manufacturing services to produce drug substance at large scale for up to five years, originally valued at approximately $480 million in the first two contract years. At the time of the Notice, it is the Company’s position that the payments owed to the Company by Janssen, if the Agreement were to be terminated, would be in the estimated range of approximately $125 million to $420 million.
Emergent BioSolutions Inc. Presents at Benchmark 2022 Healthcare House Call Virtual Conference, Jun-02-2022
2022-06-02 12:20:00
Emergent BioSolutions Inc. Presents at Benchmark 2022 Healthcare House Call Virtual Conference, Jun-02-2022 .
Emergent BioSolutions Inc. Presents at NYSE Healthcare & Technology Investor Access Day, Jun-08-2022
2022-06-02 12:20:00
Emergent BioSolutions Inc. Presents at NYSE Healthcare & Technology Investor Access Day, Jun-08-2022 .
Emergent BioSolutions Inc. Presents at Three Part Advisors 2022 East Coast IDEAS Conference, Jun-22-2022 06:00 AM
2022-06-02 02:01:00
Emergent BioSolutions Inc. Presents at Three Part Advisors 2022 East Coast IDEAS Conference, Jun-22-2022 06:00 AM.
Emergent BioSolutions Inc. Presents at Singular Research’s Spring Select Webinar, May-25-2022 06:15 AM
2022-05-24 12:07:00
Emergent BioSolutions Inc. Presents at Singular Research’s Spring Select Webinar, May-25-2022 06:15 AM.
Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million.
2022-05-16 00:00:00
Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million on May 15, 2022. Under the terms of the agreement with Emergent, Chimerix will receive $225 million upon closing of the transaction plus up to $100 million in up to four $25 million milestone payments. Each milestone payment is contingent upon the exercise of future BARDA procurement options of TEMBEXA following the base period. The closing payment and the milestone payments may be adjusted based on actual procurement value. Chimerix is also eligible to receive up to $12.5 million in regulatory milestones associated with the SymBio Pharmaceuticals Ltd. brincidofovir partnership to be assumed by Emergent. Chimerix may also earn a 20% royalty on future gross profit of TEMBEXA in the United States associated with volumes above 1.7 million treatment courses of therapy during the exclusivity period of TEMBEXA. Outside of the United States, the agreement also allows Chimerix to earn a 15% royalty on all gross profit associated with TEMBEXA sales during the exclusivity period of TEMBEXA on a market-to-market basis. The transaction will be funded with Emergent's currently available funds. The transaction is subjected to the satisfaction or waiver of customary conditions, approval from BARDA and the expiration or early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act). The companies expect the transaction to close as early as the second quarter of 2022. Centerview Partners LLC acted as financial advisor and Jason Kent and Ian Nussbaum of Cooley LLP acted as legal counsel to Chimerix. Todd Overman and John Fuller of Bass, Berry & Sims PLC acted as legal counsel to Emergent BioSolutions.
The Benchmark Company, LLC, Benchmark 2022 Healthcare House Call Virtual Conference, Jun 02, 2022
2022-05-13 21:54:00
The Benchmark Company, LLC, Benchmark 2022 Healthcare House Call Virtual Conference, Jun 02, 2022.
Emergent BioSolutions Seeks M&A
2022-05-10 19:00:00
Emergent BioSolutions Inc. (NYSE:EBS) is looking for M&A. Rich Lindahl, Chief Financial Officer said, “The third is to evaluate and invest in attractive M&A opportunities. We're looking for opportunities that expand the surface area of public health threats and solutions that we provide to those threats. And we look for opportunities that are, first and foremost, revenue-generating and accretive in nature. We also are interested in and acquiring additional candidates to enhance and expand our pipeline. We take a very disciplined approach there. And they need to not only fit our strategic criteria, but obviously make good financial sense for the company”.
Three Part Advisors, LLC, Three Part Advisors 2022 East Coast IDEAS Conference, Jun 22, 2022 through Jun 23, 2022
2022-05-09 17:22:00
Three Part Advisors, LLC, Three Part Advisors 2022 East Coast IDEAS Conference, Jun 22, 2022 through Jun 23, 2022.
Tranche Update on Emergent BioSolutions Inc. (NYSE:EBS)'s Equity Buyback Plan announced on November 11, 2021.
2022-04-29 10:16:00
From January 1, 2022 to March 31, 2022, the company has repurchased 1,123,868 shares, representing 2.19% for $52.18 million. With this, the company has completed the repurchase of 3,758,666 shares, representing 7.09% for $164.6 million under the buyback announced on November 11, 2021.
Emergent Biosolutions Inc. Temporarily Suspends Guidance for the Year 2022
2022-04-28 20:05:00
Emergent BioSolutions Inc. temporarily Suspended Guidance for the year 2022. Following the recent decision by Johnson & Johnson (J&J) to suspend projecting COVID-19 vaccine sales for 2022 due to global supply surplus and vaccine hesitancy in the developing world, the Company's 2022 revenues related to its commercial supply arrangement with J&J are uncertain. Accordingly, the following metrics are temporarily suspended for full year 2022 pending further clarity on J&J COVID-19 vaccine requirements: CDMO Revenues, Total Revenues.
I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022
2022-04-23 07:45:00
I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022. Venue: Boston, Massachusetts, United States.
Emergent BioSolutions Inc. - Shareholder/Analyst Call
2022-04-15 20:52:00
AGM
Emergent BioSolutions Inc., Annual General Meeting, May 26, 2022
2022-04-15 20:52:00
Emergent BioSolutions Inc., Annual General Meeting, May 26, 2022, at 09:00 Eastern Daylight. Agenda: To elect three Class I directors to hold office for a term expiring at 2025 annual meeting of stockholders, each to serve until their respective successors are duly elected and qualified; to ratify the appointment by the audit committee of Ernst & Young LLP as company's Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2022; to hold, on an advisory basis, a vote to approve executive compensation; and to act upon any other matter that may properly come before the meeting or any adjournment or postponement of the meeting.
Emergent BioSolutions Inc., Q1 2022 Earnings Call, Apr 28, 2022
2022-04-08 10:30:00
Emergent BioSolutions Inc., Q1 2022 Earnings Call, Apr 28, 2022
Emergent BioSolutions Inc. to Report Q1, 2022 Results on Apr 28, 2022
2022-04-08 10:30:00
Emergent BioSolutions Inc. announced that they will report Q1, 2022 results on Apr 28, 2022
Singular Research, LLC, Singular Research’s Spring Select Webinar, May 25, 2022
2022-03-23 21:09:00
Singular Research, LLC, Singular Research’s Spring Select Webinar, May 25, 2022.
Emergent BioSolutions Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 12:00 PM
2022-03-14 20:05:00
Emergent BioSolutions Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 12:00 PM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Richard S. Lindahl, Executive VP, CFO & Treasurer, Robert G. Burrows, Vice President of Investor Relations.
The Goldman Sachs Group, Inc., Goldman Sachs 7th Annual Leveraged Finance and Credit Conference, May 11, 2022 through May 13, 2022
2022-03-14 20:05:00
The Goldman Sachs Group, Inc., Goldman Sachs 7th Annual Leveraged Finance and Credit Conference, May 11, 2022 through May 13, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
Emergent BioSolutions Inc. Presents at Goldman Sachs 7th Annual Leveraged Finance and Credit Conference, May-12-2022 01:40 PM
2022-03-14 20:05:00
Emergent BioSolutions Inc. Presents at Goldman Sachs 7th Annual Leveraged Finance and Credit Conference, May-12-2022 01:40 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
Tranche Update on Emergent BioSolutions Inc. (NYSE:EBS)'s Equity Buyback Plan announced on November 11, 2021.
2022-02-25 16:35:00
From November 11, 2021 to December 31, 2021, the company has repurchased 2,634,798 shares, representing 4.9% for $112.42 million. With this, the company has completed the repurchase of 2,634,798 shares, representing 4.9% for $112.42 million under the buyback announced on November 11, 2021.
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022
2022-02-17 10:42:00
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.
NYSE Holdings LLC, NYSE Healthcare & Technology Investor Access Day, Jun 08, 2022
2022-02-05 02:02:00
NYSE Holdings LLC, NYSE Healthcare & Technology Investor Access Day, Jun 08, 2022.
Emergent BioSolutions Inc Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
2021-12-16 12:30:00
Emergent BioSolutions Inc. announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate. This current version of Emergent’s universal influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses. The goal of this single-center, randomized, double blind, placebo-controlled dose-escalation study is to evaluate the safety, tolerability, and immunogenicity of the vaccine candidate at two dose levels and two schedules in 60 healthy adult individuals aged 18 to 45. This phase 1 study, being conducted in Australia, is fully funded by Emergent. Emergent’s universal influenza vaccine candidate is based on a nanoparticle vaccine that self-assembles during production and that displays a cross-reactive hemagglutinin (HA) antigen for influenza virus A groups 1 and 2. The self-assembling HA stabilized stem nanoparticle technology was developed by and licensed from the National Institute of Allergy and Infectious Diseases Vaccine Research Center.
Emergent BioSolutions Inc. Presents at Singular Research “Best of The Uncovereds”, Dec-09-2021 09:45 AM
2021-12-10 12:34:00
Emergent BioSolutions Inc. Presents at Singular Research “Best of The Uncovereds”, Dec-09-2021 09:45 AM. Speakers: Robert G. Burrows, Vice President of Investor Relations.
Singular Research, LLC, Singular Research “Best of the Uncovereds”, Dec 09, 2021
2021-11-30 13:58:00
Singular Research, LLC, Singular Research “Best of The Uncovereds”, Dec 09, 2021.
Emergent BioSolutions Inc.(NYSE:EBS) added to S&P 600
2021-11-30 00:00:00
Emergent BioSolutions Inc.(NYSE:EBS) added to S&P 600
Emergent BioSolutions Inc.(NYSE:EBS) added to S&P 600 Health Care (Sector)
2021-11-30 00:00:00
Emergent BioSolutions Inc.(NYSE:EBS) added to S&P 600 Health Care (Sector)
Emergent BioSolutions Inc.(NYSE:EBS) dropped from S&P 400
2021-11-23 00:00:00
Emergent BioSolutions Inc.(NYSE:EBS) dropped from S&P 400
Emergent BioSolutions Inc.(NYSE:EBS) dropped from S&P 400 Health Care (Sector)
2021-11-23 00:00:00
Emergent BioSolutions Inc.(NYSE:EBS) dropped from S&P 400 Health Care (Sector)
Emergent BioSolutions Inc.(NYSE:EBS) dropped from S&P 400 - Biotechnology (Industry)
2021-11-23 00:00:00
Emergent BioSolutions Inc.(NYSE:EBS) dropped from S&P 400 - Biotechnology (Industry)
Emergent BioSolutions Inc. (NYSE:EBS) announces an Equity Buyback for $250 million worth of its shares.
2021-11-11 21:05:00
Emergent BioSolutions Inc. (NYSE:EBS) announces a share repurchase program. Under the program, the company will repurchase up to $250 million worth of its common stock. Any repurchased shares will be held in treasury shares and will be available for use in connection with the company's stock plans and for other corporate purposes. The repurchase program will be funded using the company's cash on hand and cash from operations. The program is valid till November 11, 2022. As of September 30, 2021, the company had approximately 53,700,000 shares of common stock outstanding
Emergent BioSolutions Inc. authorizes a Buyback Plan.
2021-11-11 00:00:00
The Board of Directors of Emergent BioSolutions Inc. has authorized a buyback plan on November 11, 2021.
Emergent BioSolutions Inc. Presents at 13th Annual Southwest IDEAS Investor Conference, Nov-18-2021 10:15 AM
2021-11-10 03:01:00
Emergent BioSolutions Inc. Presents at 13th Annual Southwest IDEAS Investor Conference, Nov-18-2021 10:15 AM. Venue: Westin Dallas Downtown, Dalllas, Texas, United States.
Emergent BioSolutions Seeks M&A
2021-11-04 21:00:00
Emergent BioSolutions Inc. (NYSE:EBS) is seeking M&A. Robert G. Kramer President and Chief Executive Officer said during the Third Quarter 2021 Financial Results Conference Call, "Our third quarter operational results demonstrate that our business remains resilient and poised for growth in line with our strategy. We continue on our path of both organic opportunities and potential M&A informed by prudent capital deployment, all aimed at generating enhanced shareholder value".
Emergent Biosolutions Inc. and Biomedical Advanced Research and Development Authority Enter into Contract Modifications
2021-11-04 20:19:00
Emergent BioSolutions Inc. and Biomedical Advanced Research and Development Authority (“BARDA”), an agency under the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (“HHS”) entered into contract modifications (the “Modifications”) under which the parties mutually agreed to terminate the U.S. Government and Emergent's Center for Innovation in Advanced Development and Manufacturing Contract (the “CIADM Contract”) to establish a public-private partnership for pandemic preparedness, issued on June 5, 2012, along with all associated task orders, including the task order issued on May 30, 2020 to reserve capacity and expand manufacturing of third-party COVID-19 vaccines and therapeutics at various Emergent sites (the “Task Order”), in support of the U.S. Government’s efforts to respond to the COVID-19 pandemic.
Emergent BioSolutions Inc. to Report Q3, 2021 Results on Nov 04, 2021
2021-10-18 10:32:00
Emergent BioSolutions Inc. announced that they will report Q3, 2021 results on Nov 04, 2021
Emergent BioSolutions Inc., Q3 2021 Earnings Call, Nov 04, 2021
2021-10-18 10:30:00
Emergent BioSolutions Inc., Q3 2021 Earnings Call, Nov 04, 2021
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
2021-10-15 10:30:00
Emergent BioSolutions Inc. announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, in a single dose. CHIKV VLP is the only VLP-based vaccine currently in clinical development for active immunization against chikungunya disease. The goal of this multi-center, randomized, double blind, placebo-controlled study is to evaluate the safety and immunogenicity of the CHIKV VLP vaccine candidate in healthy individuals aged 12 to 64 as well as to demonstrate the consistency of the chikungunya virus (CHIKV) serum neutralizing antibody (SNA) response across three manufactured vaccine candidate lots. The study will observe the CHIKV SNA response at day 22 as measured by geometric mean titer and seroresponse rate and will enroll at least 3,150 participants in up to 49 U.S. sites. The structure of the CHIKV VLP is nearly identical to the wild-type virus but does not pose a risk of replication. Studies have shown that in general, other VLP vaccines are highly immunogenic, safe, and typically elicit high titer neutralizing antibodies, which are needed to protect against chikungunya virus.i,ii There is currently no licensed vaccine, VLP or otherwise, to prevent chikungunya virus disease.
Emergent BioSolutions Inc. Presents at World Antiviral Congress 2021, Nov-30-2021 05:10 PM
2021-09-24 19:02:00
Emergent BioSolutions Inc. Presents at World Antiviral Congress 2021, Nov-30-2021 05:10 PM. Venue: San Diego, California, United States. Speakers: Adeela Kamal, Vice-President R&D, Therapeutics.
Terrapinn Inc, World Antiviral Congress 2021, Nov 30, 2021 through Dec 02, 2021
2021-09-23 19:35:00
Terrapinn Inc, World Antiviral Congress 2021, Nov 30, 2021 through Dec 02, 2021. Venue: San Diego, California, United States.
Emergent BioSolutions Inc. Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics
2021-09-14 11:58:00
Emergent BioSolutions Inc. and Providence Therapeutics announced they have entered into a five-year contract development and manufacturing (CDMO) services agreement spanning Emergent's integrated capabilities, including development services, bulk drug substance formulation and drug product manufacturing, to support Providence's COVID-19 messenger RNA (mRNA) vaccine development. In 2022, Emergent will manufacture tens of millions of doses of PTX-COVID19-B drug product, as well as batches of PTX-COVID19-B formulated bulk drug substance with the potential to yield hundreds of millions more doses, for global populations in need of pandemic relief. Under the terms of the five-year agreement, Emergent will provide current Good Manufacturing Practice (cGMP) manufacturing services for two presentations of the PTX-COVID19-B vaccine product, both the formulated bulk drug substance and finished drug product (fill/finish), at Emergent's facility in Winnipeg, MB, Canada. Additional process and analytical development services will occur from Emergent's Center of Excellence for Development Services in Gaithersburg, Maryland. The baseline agreement signed between Emergent and Providence Therapeutics is valued at approximately $90 million, covering manufacturing services, studies to support global supply chain activities, as well as facility and equipment investments.
Emergent BioSolutions Inc. Presents at PDA Pharmaceutical Microbiology Conference, Oct-04-2021
2021-08-27 11:21:00
Emergent BioSolutions Inc. Presents at PDA Pharmaceutical Microbiology Conference, Oct-04-2021 . Venue: Washigton, District Of Columbia, United States. Speakers: Marcia C. Baroni.
Parenteral Drug Association, PDA Pharmaceutical Microbiology Conference, Oct 04, 2021 through Oct 06, 2021
2021-08-27 10:55:00
Parenteral Drug Association, PDA Pharmaceutical Microbiology Conference, Oct 04, 2021 through Oct 06, 2021. Venue: Washigton, District Of Columbia, United States.
Emergent BioSolutions Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 04:00 PM
2021-08-23 20:05:00
Emergent BioSolutions Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 04:00 PM. Venue: New York, United States.
Singular Research, LLC, Singular Research Compelling Values 2021 Webinar, Sep 16, 2021
2021-08-23 20:05:00
Singular Research, LLC, Singular Research Compelling Values 2021 Webinar, Sep 16, 2021.
Emergent BioSolutions Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 03:30 PM
2021-08-23 20:05:00
Emergent BioSolutions Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 03:30 PM. Venue: New Windsor, United States.
Emergent BioSolutions Inc. Presents at Singular Research Compelling Values 2021 Webinar, Sep-16-2021 07:45 AM
2021-08-23 20:05:00
Emergent BioSolutions Inc. Presents at Singular Research Compelling Values 2021 Webinar, Sep-16-2021 07:45 AM. Speakers: Robert G. Burrows, Vice President of Investor Relations.
Emergent BioSolutions Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 04:55 PM
2021-08-23 20:05:00
Emergent BioSolutions Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 04:55 PM. Speakers: Bob Burrows, VP, IR, Richard S. Lindahl, Executive VP, CFO & Treasurer.
Emergent BioSolutions Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 through Dec-02-2021
2021-08-18 15:33:00
Emergent BioSolutions Inc. Presents at World Vaccine & Immunotherapy Congress West Coast 2021, Nov-30-2021 through Dec-02-2021. Venue: Loews Coronado Bay Resort, San Diego, California, United States. Presentation Date & Speakers: Dec-02-2021. Nov-30-2021, Adeela Kamal, VP R&D Therapeutics.
Emergent BioSolutions Inc. Presents at 12th Annual Midwest IDEAS Virtual Conference, Aug-25-2021 08:00 AM
2021-08-10 14:07:00
Emergent BioSolutions Inc. Presents at 12th Annual Midwest IDEAS Virtual Conference, Aug-25-2021 08:00 AM.
Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021
2021-08-10 13:03:00
Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.
Emergent BioSolutions Inc. has filed a Shelf Registration.
2021-08-09 00:00:00
Emergent BioSolutions Inc. has filed a Shelf Registration. Security Name: Debt Securities Security Name: Common Stock Security Name: Preferred Stock Security Name: Depositary Shares Security Name: Units Security Name: Warrants Transaction Features: Omnibus/Universal Shelf Registration
Emergent BioSolutions Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2021
2021-07-29 20:05:00
Emergent BioSolutions Inc. provided earnings guidance for the third quarter and full year of 2021. For the year, the company expects total revenues of $1,700 million to $1,900 million. For the third quarter of 2021, the company expects total revenues of $400 million to $500 million.
Emergent BioSolutions Inc. to Resume Manufacturing Covid-19 Vaccine At Bayview Facility
2021-07-29 11:24:00
Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid-19 vaccine bulk drug substance. This resumption of manufacturing follows extensive reviews by FDA, weeks of diligent work, and close coordination with J&J and FDA to execute on Emergent’s quality enhancement plan. Since production was paused at Bayview, Emergent has worked closely with FDA and J&J to address quality concerns including developing and executing an action plan and committing extensive resources to bring operations up to FDA’s exacting standards. Emergent expects to continue to work with FDA throughout the manufacturing process to help ensure the strength of the J&J Covid-19 vaccine supply chain.
Emergent Biosolutions Inc. Announces Adam Havey Expands Role to Executive Vice President and Chief Operating Officer, Principal Operating Officer
2021-07-22 20:51:00
On July 20, 2021, the Board of Directors of Emergent BioSolutions Inc. (the “Company”) approved a proposal made by the Chief Executive Officer to reorganize the responsibilities of members of the executive management team reporting to the Chief Executive Officer. In connection with that reorganization, Adam Havey’s role is expanded to Executive Vice President and Chief Operating Officer of the Company. This reorganization and Mr. Havey’s appointment as the Company’s principal operating officer are effective as of July 26, 2021.
Emergent BioSolutions Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 09:20 AM
2021-07-22 14:24:00
Emergent BioSolutions Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 09:20 AM. Speakers: Adam R. Havey, Executive Vice President of Business Operations, Robert G. Burrows, Vice President of Investor Relations, Robert G. Kramer, CEO, President & Executive Director.
Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021
2021-07-22 09:08:00
Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.
Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021
2021-07-22 01:45:00
Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021. Venue: Loews Coronado Bay Resort, San Diego, California, United States.
Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021
2021-07-22 01:45:00
Terrapinn Holdings Ltd, World Vaccine & Immunotherapy Congress West Coast 2021, Nov 30, 2021 through Dec 02, 2021. Venue: Loews Coronado Bay Resort, San Diego, California, United States.
Three Part Advisors, LLC, 13th Annual Southwest IDEAS Investor Conference, Nov 17, 2021 through Nov 18, 2021
2021-07-20 07:09:00
Three Part Advisors, LLC, 13th Annual Southwest IDEAS Investor Conference, Nov 17, 2021 through Nov 18, 2021. Venue: Westin Dallas Downtown, Dalllas, Texas, United States.
Emergent BioSolutions Inc., Q2 2021 Earnings Call, Jul 29, 2021
2021-07-15 10:30:00
Emergent BioSolutions Inc., Q2 2021 Earnings Call, Jul 29, 2021
Emergent BioSolutions Inc. to Report Q2, 2021 Results on Jul 29, 2021
2021-07-15 10:30:00
Emergent BioSolutions Inc. announced that they will report Q2, 2021 results on Jul 29, 2021
Three Part Advisors, LLC, 12th Annual Midwest IDEAS Virtual Conference, Aug 25, 2021 through Aug 26, 2021
2021-07-14 20:22:00
Three Part Advisors, LLC, 12th Annual Midwest IDEAS Virtual Conference, Aug 25, 2021 through Aug 26, 2021.
Emergent Biosolutions Inc Receives A Contract Modification from the Office of the Assistant Secretary for Preparedness and Response
2021-07-14 10:28:00
On July 13, 2021, Emergent BioSolutions Inc. through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification from the Office of the Assistant Secretary for Preparedness and Response (“ASPR”), an agency of the U.S. Department of Health and Human Services (“HHS”), exercising and funding the second of nine annual contract term extension options (the “Second Option Exercise”) for Emergent to supply ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) into the U.S. Strategic National Stockpile (the “SNS”). The Second Option Exercise is valued at approximately $182.2 million. The Second Option Exercise was made under Emergent’s existing 10-year contract (the “Contract”) awarded by ASPR on August 30, 2019. The period of performance under the Second Option Exercise requires Emergent to deliver doses of ACAM2000 into the SNS by December 31, 2021. Therefore, the entire amount is expected to be delivered in fiscal year 2021.
Fundamental Summary
Emergent BioSolutions published its Q1 report on 2022-04-29 with positive results, but no significant factors particularly remarkable relative to its peers. This typically translates into the stock performing on par with market performance for the upcoming quarter. Therefore, they earned a total score of 65 out of 100 and a HOLD recommendation.
Emergent BioSolutions reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 9 million compared to USD 116.2 million a year ago. Revenue was USD 307.5 million compared to USD 343 million a year ago. Net loss was USD 3.7 million compared to net income of USD 69.7 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to basic earnings per share from continuing operations of USD 1.31 a year ago. Diluted loss per share from continuing operations was USD 0.07 compared to diluted earnings per share from continuing operations of USD 1.28 a year ago.
Business Description
Emergent BioSolutions, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company’s products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Sector Overview
Emergent BioSolutions is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Emergent BioSolutions's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | 10.2 | -32.5% | 77 | |
| Net Cashflow | -112.0 | -147.8% | 70 | |
| Capital Expenditure | -201.1 | 10.6% | 87 | |
| Asset Turnover | 0.6 | 0.8% | 75 | |
| Free Cashflow | 1.5 | -18.3% | 53 |
* All values are TTM
The below chart reflects Emergent BioSolutions's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Emergent BioSolutions's peer average final assessment score stands on 71.0, Emergent BioSolutions's score is 65.
- EBS
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Emergent BioSolutions's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Emergent BioSolutions's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 31.
5D MA
31.83
50D MA
32.63
200D MA
42.25
MACD
-0.43
RSI
42.3
STOCH
71.72
Balance Sheet Analysis
Equity and Assets stood out as the most significant drivers of Emergent BioSolutions's balance sheet strength. Emergent BioSolutions reported solid equity numbers this period. At filing, equity was reported as 1575.3, representing -2.7% change from the previous period. Companies in the same sector and market capitalization will usually be affected by up to 7.3 percent by this parameter. This performance is significantly more impressive than its peers and competitors. Consequently, their equity movement received a grade of 87. Also, Emergent BioSolutions assets on their balance sheet, moved to 2780.4, which is a -6.0% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. Consequently, their asset movement received a grade of 62. That said, one metric, Liabilities, stood out as strongly negative. At filing, Emergent BioSolutions's liabilities were 1205.1, representing a -10.1% change from the previous period. This performance is relatively weak in comparison to their peers and suggests that its's stock price will likely suffer until this is solved. Discouraging results like these statistically lead to negative movement in stock prices, so we rated their liabilities movement component 48. Its balance sheet received an overall score of 61.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 2,780.4 | -6.0% | 62 |
| Liabilities | 1,205.1 | -10.1% | 48 |
| Price to Book | 1.0 | -24.9% | 61 |
| Cash & Equivalents | 435.8 | -24.4% | 48 |
| Equity | 1,575.3 | -2.7% | 87 |
The below chart describes Emergent BioSolutions's performance as reflected on its balance sheet with respect to its peers. While Emergent BioSolutions received a balance sheet score of 61, the average of its peers stands on 69.0.
- EBS
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 0 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 1 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 2 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 3 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 4 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 5 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 6 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 7 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 8 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 9 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 10 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 11 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 12 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 13 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 14 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 15 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 16 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 17 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 18 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 19 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 20 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 21 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 22 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 23 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 24 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 25 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 26 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 27 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 28 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 29 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 30 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 31 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 32 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 33 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 34 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 35 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 36 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 37 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 38 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 39 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 40 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 41 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 42 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 43 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 44 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 45 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 46 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 47 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 48 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 49 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 50 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 51 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 52 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 53 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 54 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 55 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 56 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 57 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 58 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 59 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 60 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 61 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 62 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 63 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 64 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 65 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 66 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 67 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 68 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 69 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 70 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 71 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 72 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 73 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 74 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 75 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 76 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 77 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 78 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 79 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 80 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 81 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 82 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 83 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 84 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 85 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 86 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 87 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 88 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 94 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Overall, Emergent BioSolutions's critical income statement metrics appear to signal strong support and a high likelihood of positive growth going forward. Emergent BioSolutions did an excellent job managing its revenue efficiency this past period. Emergent BioSolutions's revenue efficiency is 1757.2 according to the metrics in the current filing, which represents a -2.0% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their impressive revenue efficiency is even more impressive relative to its peers and competitors in the current market. As a result, its revenue efficiency earned a score of 91. Also, In this filing, Emergent BioSolutions reported a return on equity (ROE) ratio of 10.2, which represents a change of -32.5%. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 77. However, one discouraging result, EBITDA, stood out. Emergent BioSolutions's EBIDTA now sits at 433.6 and represents -16.8% change from the last reporting period. This metric might have a 24.4 percent impact on companies in the same industry and with the same market capitalization. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Its EBITDA movement, therefore, received a grade of 51. Consequently, their income statement earned a rank of 66.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | 433.6 | -16.8% | 51 |
| Total Revenues | 1,757.2 | -2.0% | 91 |
| Return on Equity | 10.2 | -32.5% | 77 |
The below chart describes Emergent BioSolutions's performance as reflected on its income statement with respect to its peers. While Emergent BioSolutions received a income statement score of 66 , the average of its peers stands on 70.0.
- EBS
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 0 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 1 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 2 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 3 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 4 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 5 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 6 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 7 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 8 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 9 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 10 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 11 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 12 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 13 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 14 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 15 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 16 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 17 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 18 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 19 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 20 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 21 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 22 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 23 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 24 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 25 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 26 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 27 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 28 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 29 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 30 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 31 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 32 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 33 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 34 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 35 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 36 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 37 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 38 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 39 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 40 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 41 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 42 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 43 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 44 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 45 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 46 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 47 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 48 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 49 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 50 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 51 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 52 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 53 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 54 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 55 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 56 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 57 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 58 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 59 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 60 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 61 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 62 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 63 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 64 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 65 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 66 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 67 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 68 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 69 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 70 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 71 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 72 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 73 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 74 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 75 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 76 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 77 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 78 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 79 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 80 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 81 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 82 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 83 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 84 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 85 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 86 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 87 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 88 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 94 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Overall, Emergent BioSolutions's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. Emergent BioSolutions's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -201.1, which represents a 10.6% change from the last period. The company appears to be headed in the right direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Therefore, its CapEx movement component earned a score of 87. Also, Emergent BioSolutions's published asset turnover numbers were encouraging and reflected management's balanced change strategy. Emergent BioSolutions recorded asset turnover of 0.6, which represents a 0.8% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Its asset turnover metrics are especially remarkable relative to their peers. We believe the stock price has room to grow to reflect its intrinsic value accurately. Therefore, its asset turnover movement earned a score of 75. That said, one metric, Free Cash flow, stood out as strongly negative. Free cash flow numbers published by Emergent BioSolutions were 1.5, which was a -18.3% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. These free cash flow numbers show that management has not been executing well in generating critical cash flow while also encouraging growth. Consequently, their free cash flow movement received a grade of 53. Consequently, the company's cash flow earned a score of 75.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -112.0 | -147.8% | 70 |
| Capital Expenditure | -201.1 | 10.6% | 87 |
| Asset Turnover | 0.6 | 0.8% | 75 |
| Free Cashflow | 1.5 | -18.3% | 53 |
The below chart describes Emergent BioSolutions's performance as reflected on its cash flow with respect to its peers. While Emergent BioSolutions received a cash flow score of 75, the average of its peers stands on 71.0.
- EBS
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 0 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 1 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 2 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 3 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 4 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 5 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 6 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 7 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 8 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 9 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 10 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 11 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 12 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 13 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 14 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 15 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 16 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 17 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 18 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 19 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 20 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 21 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 22 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 23 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 24 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 25 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 26 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 27 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 28 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 29 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 30 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 31 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 32 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 33 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 34 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 35 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 36 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 37 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 38 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 39 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 40 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 41 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 42 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 43 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 44 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 45 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 46 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 47 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 48 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 49 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 50 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 51 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 52 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 53 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 54 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 55 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 56 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 57 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 58 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 59 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 60 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 61 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 62 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 63 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 64 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 65 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 66 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 67 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 68 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 69 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 70 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 71 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 72 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 73 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 74 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 75 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 76 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 77 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 78 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 79 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 80 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 81 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 82 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 83 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 84 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 85 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 86 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 87 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 88 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 94 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.